LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain.
LASSBio-1135 is an imidazo[1,2-a]pyridine derivative with high efficacy in screening models of nociception and inflammation, presumed as a weak COX-2 inhibitor. In order to tease out its mechanism of action, we investigated others possible target for LASSBio-1135, such as TNF-α and TRPV1, to better...
Main Authors: | Cleverton K F Lima, Rafael M Silva, Renata B Lacerda, Bruna L R Santos, Rafaela V Silva, Luciana S Amaral, Luís E M Quintas, Carlos A M Fraga, Eliezer J Barreiro, Marília Z P Guimaraes, Ana L P Miranda |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24941071/?tool=EBI |
Similar Items
-
Impairment of locomotor activity induced by the novel N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice
by: G.A.P. Silva, et al.
Published: (2013-03-01) -
Impairment of locomotor activity induced by the novel N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice
by: G.A.P. Silva, et al.
Published: (2013-01-01) -
LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A2A Receptor
by: Vinicius F. Carvalho, et al.
Published: (2017-10-01) -
High performance liquid chromatography method for quantification of the N-phenylpiperazine derivative LASSBio-579 in rat plasma
by: Daniela J. Conrado, et al.
Published: (2007-01-01) -
Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema
by: Gisele A Padilha, et al.
Published: (2015-09-01)